ESKD

DGAP-News: MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Constellation, Society, Population, Cancer, Industry, Clinical trial, Immunoglobulin G, FSE, Food, Lymphoma, Ohio, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chronic kidney disease, Nephrotic syndrome, Lenalidomide, Diagnosis, Communication, A2, Risk, China, Safety, Kidney, Cyclophosphamide, MM, Glomerulonephritis, Ohio State University, B cell, Poster, Patient, U.S. Securities and Exchange Commission, NASDAQ, Disease, Inflammation, Steroid, Psoriasis, Janssen Pharmaceuticals, Time-invariant system, LLC, Multiple myeloma, Proteinuria, ESKD, Joint Planning and Development Office, University, MD, BLA, Trial of the century, Annual report, Podocyte, Judgement, Incidence, Antibody, Degenerative disease, C1-inhibitor, ASN, Autoantibody, UPCR, Plasma protein binding, CD38, Pharmaceutical industry, Vaccine, Membranous Nephropathy (MN), MorphoSys, MEMBRANOUS NEPHROPATHY (MN), MORPHOSYS

MorphoSys AG (FSE: MOR; NASDAQ: MOR) presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN) on November 4-7.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN) on November 4-7.
  • Of the 27 treated patients with evaluable results, 24 showed an initial rapid reduction of anti-PLA2R antibody levels one week after the first treatment.
  • Safety profile was consistent with the proposed mechanism of action of felzartamab and treatment-emergent adverse events were manageable.
  • Felzartamab (MOR202/TJ202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38.

Somatus and Anthem, Inc. Collaborate to Deliver Personalized, Value-Based Kidney Care

Retrieved on: 
Wednesday, November 3, 2021
Biotechnology, Health, Clinical Trials, Other Health, ANTM, Nephrology, Hospital, Kidney transplantation, Twitter, Partnership, Anthem Inc. (album), Patient, NYSE, Chronic kidney disease, Anthem, Risk, ESKD, Kidney, Company, Medicare, Growth, Kidney disease, CKD, Health, HIV disease progression rates, Health insurance, Somatus, Anthem, Inc., SOMATUS, ANTHEM, INC.

Somatus, a market leader in value-based kidney care, today announced a long-term, multi-year partnership with Anthem, Inc (NYSE: ANTM).

Key Points: 
  • Somatus, a market leader in value-based kidney care, today announced a long-term, multi-year partnership with Anthem, Inc (NYSE: ANTM).
  • Together, Anthem and Somatus will change how kidney care is experienced and delivered for members of Anthems affiliated Medicare Advantage plans, specifically individuals with chronic kidney disease (CKD) Stage 3, 4, and 5 and end-stage kidney disease (ESKD).
  • Somatus partnership with Anthem expands the Companys geographic footprint to 34 states and increases its kidney care lives under management to more than 150,000.
  • The Companys impressive growth across all kidney care stakeholders reflects its demonstrated ability to improve quality of care and lower costs for patients with kidney disease.

Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021

Retrieved on: 
Tuesday, November 2, 2021
Safety, Irbesartan, 2021 Essex County Council election, Treatment, SAN, Association, Inflammation, Focal segmental glomerulosclerosis, Proteinuria, Impact, Patient, NASDAQ, II, ASN, Chronic kidney disease, Immunoglobulin A, Vasculitis, ESKD, American Society of Nephrology, Company, TMA, Caregiver, Podocyte, Heart Protection Study, Therapy, UK National Kidney Federation, Society, GLOBE, Glomerulosclerosis, Lupus nephritis, Kidney, Pharmaceutical industry, Dentistry, Online gambling, Hatmaking

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021.

Key Points: 
  • SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021.
  • ASN Kidney Week 2021 is being held virtually November 4-7, 2021.
  • All ePosters will be made available to ASN Kidney Week 2021 participants on November 4, 2021 at 10:00 a.m. PT, and will be accessible on-demand through January 7, 2022.
  • Sparsentan has been granted Orphan Drug Designation for the treatment of FSGS and IgAN in the U.S. and Europe.

Cricket Health Names New Chief Commercial Officer Ryan M. Jacobs

Retrieved on: 
Wednesday, October 27, 2021
Population health, Technology, Architecture, Nephrology, SAN, Jacobs, Optum, HITRUST, Medicare Advantage, Patient, Chronic kidney disease, Telephone, Risk, Leadership, ESKD, Cricket, Marketing, Medicare, GFR, Growth, Multimedia, Kidney disease, CKD, Health, News, Population, Health insurance

SAN FRANCISCO, Oct. 27, 2021 /PRNewswire/ --Cricket Health, an industry-leading value-based kidney care provider, today announced that Ryan Jacobs has joined the company's executive team as chief commercial officer.

Key Points: 
  • SAN FRANCISCO, Oct. 27, 2021 /PRNewswire/ --Cricket Health, an industry-leading value-based kidney care provider, today announced that Ryan Jacobs has joined the company's executive team as chief commercial officer.
  • Jacobs will oversee all commercial strategy, growth, network development, and marketing for Cricket.
  • "Having worked in the health care industry for more than 20 years, I understand the immense potential of value-based care.
  • Cricket works with Medicare Advantage, commercial plans, and nephrology practices throughout the U.S.
    "Ryan brings a strong desire to better people's lives along with more than two decades of experience in the population health, value-based care, health care consulting, and digital health spaces," said Cricket Health CEO Robert Sepucha.

Somatus Becomes Only Value-based Kidney Care Management Provider to Receive NCQA Accreditation for Both Population Health and Case Management

Retrieved on: 
Wednesday, October 20, 2021
Insurance, Finance, Hospitals, Professional Services, Practice Management, Other Health, Managed Care, Health, Other Professional Services, Quality, NCQA, Risk, Chronic kidney disease, Nephrology, Kidney, Kidney disease, Organization, ESKD, LinkedIn, National Committee, CM, Â, Goal, Population health, Case management, Facebook, Information set, CKD, International healthcare accreditation, Accreditation, HIV disease progression rates, Population Health Management, Patient, Health, PHP, Review, Kidney transplantation, Population, Data management, Medicine, Health insurance, Pharmaceutical industry, Somatus, NCQA, SOMATUS, NCQA

Somatus, the nations leading provider of value-based kidney care, today announced its kidney care management program has been awarded the National Committee for Quality Assurances (NCQA) Population Health Program (PHP) and Case Management (CM) Accreditations.

Key Points: 
  • Somatus, the nations leading provider of value-based kidney care, today announced its kidney care management program has been awarded the National Committee for Quality Assurances (NCQA) Population Health Program (PHP) and Case Management (CM) Accreditations.
  • Somatus is the only value-based kidney care management provider to receive simultaneous NCQA accreditation for both PHP and CM.
  • Case Management and Population Health Management accreditation move us closer to measuring quality and the increased focus on person-centered care across population health initiatives, said Margaret E. OKane, President, NCQA.
  • It is extremely rewarding to receive NCQA accreditation for both our population health and case management work, said Dr. Abi Sundaramoorthy, Somatus Executive Vice President of Clinical Enterprise.

Strive Health Unveils Strive Care Partners, Reaches 500 Nephrology Partners

Retrieved on: 
Tuesday, October 19, 2021
Technology, Diabetes, Other Technology, Software, Practice Management, Other Health, Managed Care, Health, Data Management, Government, Kidney disease, Renal Association, CDC, Chronic kidney disease, Technology, Twitter, Nephrology, ESKD, LinkedIn, Lead, CEO, CKD, New Enterprise Associates, Patient, 21st Century Cures Act, CapitalG, Partnership, MA, International Pediatric Nephrology Association, Physician, Kidney failure, SCP, Health insurance, Risk management, Medicine, Video game, Pharmaceutical industry

Strive Health , the national leader in value-based kidney care, today announced Strive Care Partners (SCP), which is a dedicated platform that enables nephrologists to share and succeed in global risk contracts with payors.

Key Points: 
  • Strive Health , the national leader in value-based kidney care, today announced Strive Care Partners (SCP), which is a dedicated platform that enables nephrologists to share and succeed in global risk contracts with payors.
  • Our value-based kidney care platform was built from day one for nephrologist integration and enablement, said Chris Riopelle, CEO and co-founder of Strive Health.
  • Companies such as Agilon Health and Oak Street Health have empowered primary care physicians to shift to risk-based models over the past several years, and Strive Health is leading a similar physician-led transformation in nephrology care.
  • Strive's core services include Strive Population Health, Strive Care Partners and Strive Complete Dialysis.

Global Renal Care Management Growth Opportunities Report 2021: Enhancing Remote Management Capabilities for Rapid Expansion of Peritoneal and Home Hemodialysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 29, 2021
Medical Devices, Health, Heart failure, Kidney disease, Adoption, ESKD, Solution, Chronic kidney disease, Ageing, Statistics, Cancer, Patient, Population, Dialysis, Fresenius, Hypertension, Kidney, Diabetes, Specialization, Technology, CKD, Comorbidity, Diaverum, Council for Affordable Quality Healthcare, Pharmaceutical industry

The "Global Renal Care Management Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Care Management Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • Along with rising aging population, increasing number of CKD patients are suffering from comorbidities such as hypertension, diabetes, heart failure, cancer, and mental ill health.
  • Renal care management has been expanding from the stage of just caring for End Stage Renal Disease (ESKD) patients to prevention of patients from developing chronic kidney diseases.
  • Renal care solution providers understand the importance of managing associated comorbid conditions and are, therefore, offering collaborative solutions that target these conditions.

Strive Health and Nation’s Largest Nephrology Group, NANI, Form Strategic Partnership to Reinvent Kidney Care Delivery

Retrieved on: 
Tuesday, September 21, 2021
Data Management, Public Policy, Government, Health, Healthcare Reform, Technology, Other Technology, General Health, Kidney disease, Chronic kidney disease, ESKD, Partnership, Health, Patient, Physician, International Pediatric Nephrology Association, LinkedIn, CDC, Twitter, CEO, Â, Medicare Advantage, Nephrology, CapitalG, Technology, CKD, Alphabet, Contract, Movement, Government, ESCO, Health insurance, Pharmaceutical industry, Medicine, NANI, Strive Health, NANI, STRIVE HEALTH

Strive Health , the national leader in value-based kidney care, and Nephrology Associates of Northern Illinois and Northern Indiana (NANI) , the nations largest independent nephrology group, today announced a strategic partnership to jointly pursue and manage global risk payment models.

Key Points: 
  • Strive Health , the national leader in value-based kidney care, and Nephrology Associates of Northern Illinois and Northern Indiana (NANI) , the nations largest independent nephrology group, today announced a strategic partnership to jointly pursue and manage global risk payment models.
  • Strive brings a shared commitment and a proven track record in value-based kidney care, and we are excited to build a long-standing strategic partnership with them as we continue to grow.
  • Strive Health is the national leader in value-based kidney care and partner of choice for innovative healthcare payors and providers.
  • Backed by New Enterprise Associates, CapitalG, Redpoint, Town Hall Ventures, Echo Health Ventures and Ascension Ventures, Strive delivers compassionate kidney care the way it should be done.

Cricket Health Achieves HITRUST CSF® Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements

Retrieved on: 
Tuesday, September 7, 2021

"That is why we are pleased to achieve HITRUST CSF certification, demonstrating that Cricket Health is meeting the highest standards for protecting sensitive health information."

Key Points: 
  • "That is why we are pleased to achieve HITRUST CSF certification, demonstrating that Cricket Health is meeting the highest standards for protecting sensitive health information."
  • HITRUST CSF Certified status demonstrates that Cricket Health has met key regulations and industry-defined requirements and is appropriately managing risk.
  • "The fact that Cricket Health has achieved HITRUST CSF Certification attests to the high quality of their information risk management and compliance program."
  • Cricket Health works with major health plans and nephrology practices to help them provide personalized, stage-specific, and patient-centered kidney care.